We're joined by Ahmet Tutuncu, CEO of AeroRx Therapeutics, to discuss their novel, best-in-class nebulized combination product for moderate-to-severe COPD patients.
AeroRx's pipeline includes AERO-007, the first nebulized LABA/LAMA combination in clinical development, and AERO-111, the first triple LABA/LAMA/ICS nebulized therapy in IND-enabling studies.
Ahmet previously co-founded Elevation Pharma and Patara Pharma, both acquired for their inhaled-drug platforms.
In a wide ranging discussion we also discuss the deal-making streak in the COPD space, starting with Merck's acquisition of Verona Pharma in mid-2025, and highlighted by the recent launch of AirNexis.
